• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
367,316 results

Mallinckrodt Pharmaceuticals Ireland Limited et al v. Airgas Therapeutics LLC et al

Docket 1:22-cv-01648, Delaware District Court (Dec. 30, 2022)
Judge Richard G. Andrews, presiding, Judge Laura D. Hatcher
Patent - Abbreviated New Drug Application (ANDA)
DivisionWilmington
FlagsDISCOVERY-LDH, Multi-Media Docs, PATENT
Cause35:1 Patent Infringement
Case Type835 Patent - Abbreviated New Drug Application (ANDA)
Tags835 Patent, Abbreviated New Drug Application, Anda, 835 Patent, Abbreviated New Drug Application, Anda
DeadlineDispositive Motions due by 3/21/2025, Answering Briefs due by 4/18/2025, Reply Briefs due by 4/25/2025.
DeadlineORDER To Extend The Deadline For The Central Authority of Sweeden to execute the letter of requests to April 30, 2025..
Plaintiff Mallinckrodt Pharmaceuticals Ireland Limited
Plaintiff Mallinckrodt Hospital Products IP Unlimited Company
Plaintiff Mallinckrodt plc
...
cite Cite Docket
Analyze

Allergan, Inc. et al v. Revance Therapeutics, Inc. et al

Docket 1:21-cv-01411, Delaware District Court (Oct. 1, 2021)
Judge Richard G. Andrews, presiding, Judge Laura D. Hatcher
Patent
DivisionWilmington
FlagsDISCOVERY-LDH, PATENT
Cause35:271 Patent Infringement
Case Type830 Patent
Tags830 Patent, 830 Patent
DeadlineRedacted Transcript Deadline set for 3/17/2025.
DeadlineSO ORDERED, re 543 STIPULATION and Proposed Order to file redacted versions of D.I. 533 and 534 by March 21, 2025., STIPULATION and Proposed Order to file redacted versions of D.I. 533 and 534 by March 21, 2025 - filed by Allergan Pharmaceuticals Ireland Unlimited Company, Allergan USA, Inc.
Plaintiff Allergan, Inc.
Plaintiff Allergan Pharmaceuticals Ireland Unlimited Company
Plaintiff Allergan USA, Inc.
...
cite Cite Docket
Analyze

No. 532 SO ORDERED Granting 531 STIPULATION and Proposed Order extending time to respond to the Court's ...

Document Allergan, Inc. et al v. Revance Therapeutics, Inc. et al, 1:21-cv-01411, No. 532 (D.Del. Feb. 14, 2025)
Motion to Extend TimeGranted
Log in to see more
cite Cite Document
Analyze

No. 346 MEMORANDUM OPINION

Document Mallinckrodt Pharmaceuticals Ireland Limited et al v. Airgas Therapeutics LLC et al, 1:22-cv-01648, No. 346 (D.Del. Feb. 12, 2025)
Case 1:22-cv-01648-RGA-LDH Document 346 Filed 02/12/25 Page 1 of 20 PageID #: 48910 Case 1:22-cv-01648-RGA-LDH Document 346 Filed 02/12/25 Page 2 of 20
cite Cite Document
Analyze

No. 526 ORDER ON MOTION TO SEAL: The motion to seal (D.I. 385 ) is GRANTED in part and DENIED in part

Document Allergan, Inc. et al v. Revance Therapeutics, Inc. et al, 1:21-cv-01411, No. 526 (D.Del. Feb. 12, 2025)
Motion to SealPartial
Case 1:21-cv-01411-RGA-LDH Document 526 Filed 02/12/25 Page 1 of 3 PageID #: 55601 Case 1:21-cv-01411-RGA-LDH Document 526 Filed 02/12/25 Page 2 of 3 PageID #: 55602 Case 1:21-cv-01411-RGA-LDH Document 526 Filed 02/12/25 Page 3 of 3 PageID #: 55603
cite Cite Document
Analyze

No. 480 ORDER: On December 20, 2024, Plaintiffs shall file a 20-page opening brief addressing the law ...

Document Allergan, Inc. et al v. Revance Therapeutics, Inc. et al, 1:21-cv-01411, No. 480 (D.Del. Dec. 16, 2024)
Revance Therapeutics, Inc. and Ajinomoto Althea, Inc. d/b/a Ajinomoto Bio-Pharma Services, Defendants.
IT IS HEREBY ORDERED, this ______ day of December 2024, that:
On December 20, 2024, Plaintiffs shall file a 20-page opening brief addressing the law and facts that they proffer they can show at trial concerning lost profits damages (see D.I.
On or before January 7, 2025, Defendants shall file a 20-page response to Plaintiffs’ brief; and
On or before January 17, 2025, Plaintiffs shall file a 10-page reply brief.
cite Cite Document
Analyze

No. 478 ORDER: As stated at the pretrial conference (D.I. 477 at 17:9-19:7), the motion (D.I. 409 ) ...

Document Allergan, Inc. et al v. Revance Therapeutics, Inc. et al, 1:21-cv-01411, No. 478 (D.Del. Dec. 3, 2024)
IRELAND UNLIMITED COMPANY, and
REVANCE THERAPEUTICS, INC., and AJINOMOTO ALTHEA, INC. d/b/a
As stated at the pretrial conference (D.I.
Paik Exh. 31 is EXCLUDED as substantive evidence.
IT IS SO ORDERED this 3rd day of December 2024.
cite Cite Document
Analyze

No. 476 BRIEFING ORDER: Whether a lost profits theory is viable is a question of law

Document Allergan, Inc. et al v. Revance Therapeutics, Inc. et al, 1:21-cv-01411, No. 476 (D.Del. Nov. 27, 2024)
A district court certified two questions for appeal, one of which was, “Can a foreign patent owner that does not sell any products in the U.S. market collect lost profits damages based on sales lost by its wholly-owned U.S. subsidiary, which is a non-exclusive licensee under the patent?” Fujitsu Ltd. v. Tellabs, Inc., 539 F. App'x 1005, 1006 (Fed. Cir. 2013).
The Federal Circuit declined to accept the appeal for reasons irrelevant to the merits.
There are more recent Federal Circuit cases with broad language suggesting the answer to the certified question may be, “No.” For example, “It is undisputed that [Plaintiff] does not itself sell any products.
Therefore, [Plaintiff] is not entitled to any lost profits damages.” Spine Solutions, Inc. v. Medtronic Sofamor Danek USA, Inc., 620 F.3d 1305, 1319 (Fed. Cir. 2010).
The parties are to agree to a briefing schedule with the usual page limits, and with Allergan going first.
cite Cite Document
Analyze
1 2 3 4 5 ... >>